Aviceda Therapeutics is developing targeted ligands that modulate inflammation by selectively interacting with specific immune cells to treat glyco-immune diseases. This approach aims to enhance therapeutic efficacy while minimizing off-target effects in patients suffering from these conditions.
Funding
$276.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Glyco-immune diseases involve inflammation driven by interactions between glycans and immune cells. Current treatments often lack specificity, leading to off-target effects and suboptimal therapeutic outcomes.
Solution
Aviceda Therapeutics develops targeted ligands designed to selectively modulate the immune response in glyco-immune diseases. Their approach focuses on enhancing therapeutic efficacy by precisely interacting with specific immune cells involved in the inflammatory process. By targeting these interactions, Aviceda aims to minimize off-target effects and improve outcomes for patients suffering from these conditions. The company leverages the body's natural immune system to achieve a more refined and effective modulation of inflammation. This targeted approach offers the potential for more precise and personalized treatments for a range of glyco-immune disorders.
Target Audience
The primary target audience includes patients suffering from glyco-immune diseases, as well as pharmaceutical companies and researchers focused on developing novel immunomodulatory therapies.
Features
- Highly selective ligands designed for maximum specificity towards target immune cells.
- Modulation of inflammation through precise interaction with glycan-immune cell interactions.
- Development of therapeutics for glyco-immune diseases.